FINHUB Insights

BSX · Q1 FY26 · Mar 31, 2026

Boston Scientific Q1 FY26: where the revenue came from and where it went

Boston Scientific Q1 FY26: revenue $5.2B (+12% year over year). Net profit $1.3B. Largest cohort Interventional Cardiology… $1.2B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
May 1, 2026 10-Q
Sankey diagram of Boston Scientific's income statement for Q1 FY26: revenue of $5.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$5.2B +12% year over year
Gross profit$3.6B 69% margin
Operating profit$1.1B 21% margin
Net profit$1.3B 26% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 5.2 100% +12%
Interventional Cardiology… 1.2 23% +11%
Electrophysiology EP 0.9 17% +24%
Global Endoscopy Endo Reporting… 0.7 13% +9%
Global Urology and Pelvic Health… 0.6 12% +2%
Cardiac Rhythm Management 0.6 12% +0%
Watchman 0.5 10% +19%
Global Neuromodulation Nm… 0.3 6% +17%
Interventional Oncology and… 0.3 6% +18%
Cost of revenue−1.631%
Gross profit3.669% margin+1pp
SG&A−1.834%+0pp
Other−0.714%+0pp
Operating profit1.121% margin+1pp
Net profit1.326%+11pp
Filing on EDGAR More quarters of BSX

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters